docetaxel anhydrous has been researched along with vorinostat in 9 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 2,529 | 181 | 1,840 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | vorinostat (IC50) |
|---|---|---|---|
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Gli1 | Mus musculus (house mouse) | 2.23 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
| Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
| Albumin | Homo sapiens (human) | 0.1072 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
| Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
| Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
| Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
| HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
| Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
| Histone deacetylase | Zea mays | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ajenjo, N; Albarrán, MI; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; Cuadrado-Urbano, M; García, AB; García-Serelde, B; Gómez de la Oliva, CA; Gómez-Casero, E; González Cantalapiedra, E; Hernández, AI; Klett, J; Martínez-González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rodríguez-Arístegui, S; Varela, C | 1 |
| Balasis, M; Bali, P; Bhalla, K; Fiskus, W; Pranpat, M; Richon, V; Rocha, K; Swaby, R; Wang, HG; Yamaguchi, H | 1 |
| Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC | 1 |
| Cao, C; Dong, WL; Tian, Y; Wang, XF; Yang, L; Zhang, XY; Zhang, ZQ; Zheng, LY | 1 |
| Choi, EK; Hwang, JJ; Jeong, SY; Jung, YJ; Kim, CS; Kim, DE; Kim, HG; Kim, Y; Park, SE | 1 |
| Liu, M; Wang, D; Wu, X; Yin, J; Zhang, D; Zhang, Y; Zhu, G | 1 |
1 review(s) available for docetaxel anhydrous and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for docetaxel anhydrous and vorinostat
| Article | Year |
|---|---|
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; Urologic Neoplasms; Vorinostat | 2012 |
7 other study(ies) available for docetaxel anhydrous and vorinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinolines; Structure-Activity Relationship; Triazoles | 2019 |
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Topics: Acetylation; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Drug Synergism; Flow Cytometry; G2 Phase; Gene Amplification; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Receptor, ErbB-2; Signal Transduction; Survivin; Taxoids; Trastuzumab; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2005 |
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; Cisplatin; Docetaxel; Drug Synergism; ErbB Receptors; Female; HEK293 Cells; Humans; Hydroxamic Acids; MAP Kinase Kinase 4; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Paclitaxel; Proteolysis; Taxoids; TOR Serine-Threonine Kinases; Vorinostat | 2015 |
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Male; Naphthalenes; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Receptors, Androgen; Signal Transduction; Tubulin; Vorinostat | 2018 |
Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
Topics: Animals; Antiprotozoal Agents; Cost-Benefit Analysis; Cryptosporidiosis; Cryptosporidium; Cryptosporidium parvum; Docetaxel; Humans; Mice; Paromomycin; Plant Breeding; Vorinostat | 2023 |